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Abstract
Background: FBN1 (15q21.1) encodes fibrillin-1, a large glycoprotein which is a major component of microfibrils
that are widely distributed in structural elements of elastic and non-elastic tissues. FBN1 variants are responsible
for the related connective tissue disorders, grouped under the generic term of type-1 fibrillinopathies, which
include Marfan syndrome (MFS), MASS syndrome (Mitral valve prolapse, Aortic enlargement, Skin and Skeletal
findings, Acromicric dysplasia, Familial ectopia lentis, Geleophysic dysplasia 2, Stiff skin syndrome, and dominant
Weill-Marchesani syndrome.
Case presentation: Two siblings presented with isolated skeletal manifestations of MFS, including severe pectus
excavatum, elongated face, scoliosis in one case, and absence of other clinical features according to Ghent criteria
diagnosis, were screened for detection of variants in whole FBN1 gene (65 exons). Both individuals were heterozygous
for the R2726W variant. This variant has been previously reported in association with some skeletal features of Marfan
syndrome in the absence of both tall stature and non-skeletal features. These features are consistent with the
presentation of the siblings reported here.
Conclusion: The presented cases confirm that the R2726W FBN1 variant is associated with skeletal features of
MFS in the absence of cardiac or ocular findings. These findings confirm that FBN1 variants are associated with a broad
phenotypic spectrum and the value of sequencing in atypical cases.
Keywords: FBN1 gene, R2726W variant, Type-1 fibrillinopathy
Background
FBN1 is located in chromosome 15q21.1, comprising
approximately 200 kb of genomic DNA, and is made up
of 65 exons [1, 2]. FBN1 encodes fibrillin-1, a large
glycoprotein with a molecular weight of approximately
350 kDa [3], a major component of 10–12 nm connective
tissue microfibrils that are widely distributed in both
elastic and non-elastic tissues; it is assembled into
extracellular matrix microfibrils, which are structural
components of connective tissues [2, 3]. Mutations in
the fibrillin-1 gene (FBN1; MIM 134797) are responsible
for disorders of the connective tissue, grouped under the
generic term of type-1 fibrillinopathies which include
Marfan syndrome (MFS/MIM 154700), MASS syndrome
[Mitral valve prolapse, Aortic enlargement, Skin and
Skeletal findings (MIM 604308)], familial ectopia lentis
(MIM 129600), geleophysic dysplasia 2 (MIM 614185),
stiff skin syndrome (MIM 184900), acromicric dysplasia
(MIM 102370) and dominant Weill-Marchesani syn-
drome 2 (MIM 608328) [4–8]. The first described and
most frequently reported condition associated with FBN1
mutations is MFS, an autosomal dominant inherited
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disorder of the connective tissue with a prevalence of 1 in
5,000 affected individuals [5].
Marfan syndrome affects the skeletal, ocular, and cardio-
vascular systems, as well as the skin, lungs and dura.
There is tremendous phenotypic variability in terms of
age of presentation (particularly in terms of cardiac and
ocular findings), tissues affected and severity of manifesta-
tions between and within families. The presence of these
clinical features in conjunction and the autosomal domin-
ant inheritance pattern are suggestive of a MFS diagnosis.
Due to the clinical variability, diagnostic criteria have been
defined for patients with or without a positive family
history of MFS [9, 10]. Revised Ghent criteria for MFS
diagnosis, establishes four scenarios in absence of family
history for a proband: Aortic root enlargement (Z-score
≥2.0) plus ectopia lentis, or with a pathogenic FBN1
variant; or with a systemic score ≥7; or with ectopia lentis
and FBN1 pathogenic variant. In the presence of familial
cases (a first-degree relative of the proband affected with
MFS), diagnosis can be established with the presence of
ectopia lentis or aortic root enlargement (Z-score ≥2.0 in
those age ≥20 years or ≥3.0 in those age <20 years) or
systemic score ≥7. Scoring of systemic features include the
presence of thumb and wrist sign (3 points), either wrist
or thumb sign (1), pectus carinatum (2), hind foot de-
formity (2), pneumothorax (2), dural ectasia (2), protru-
sio acetabuli (2), reduced upper segment/lower segment
and increased arm/length ratio and no severe scoliosis
(1), scoliosis or thoracolumbar kyphosis (1), reduced
elbow extension (1), 3/5 facial features like dolicho-
cephaly, enophtalmos, downslanting palpebral fissures,
malar hypoplasia and retrognathia (1), skin striae (1),
myopia > 3 diopters (1), mitral valve prolapse (1), pectus
excavatum or chest asymmetry (1) and plain pes planus
(1). It is clear that these criteria emphasis the cardio-
vascular and ocular manifestations as the cardinal clin-
ical features, and focuss less on the musculoskeletal
signs to systemic scores, which were more important
in the original Ghent criteria. In fact, from 16 points
evaluated in the score system, 11 correspond to skel-
etal manifestations [10, 11].
The vast majority of individuals meeting diagnostic
criteria for MFS have mutations in FNB1 [12, 13]. How-
ever, FBN1 variants may also be present in individuals
with incomplete Ghent criteria (without complete pheno-
type or with isolated findings) [13, 14]; i.e. inherited
forms affecting only one of the systems involved in
MFS, like isolated ectopia lentis, isolated ascending aortic
aneurysm and/or dissection (AAD) or skeletal manifesta-
tions [14–16]. In MFS, besides skeletal manifestations
defined in the score system, other features including but
not limited to tall stature, arachnodactyly, long slender
limbs, are frequently observed [11, 17]. Interestingly,
some families have been found to carry FBN1 gene
variants associated with isolated Marfan-like skeletal
features [18–20].
In MFS and related fibrillinopathies, the structural and
functional complexity of microfibrillin formed mainly by
fibrillin-1 is affected since the microfibrillin plays a role
in tropoelastin deposition and elastic fiber formation, in
addition to possessing an anchoring function in some
tissues. Several FBN1 variants result in the production of
abnormal fibrillin-1 proteins that, when incorporated
into microfibrils along normal fibrillin proteins, cause a
structurally inferior connective tissue [21, 22]. Among
the FBN1 mutations implicated in functional changes or
disease, a cluster located in exons 59 to 65 is associated
with the mild phenotype, typified by a lack of significant
aortic pathology [21]. Three mutually non-exclusive
models of the pathophysiology of MFS have been pro-
posed: a dominant negative model, disturbance of tissue
homeostasis, and increased susceptibility of fibrillin to
proteolysis [7, 23]. Although genotype–phenotype correla-
tions have been attempted, few potential ones have
emerged, and the underlying molecular correlates remain
unclear [12–14].
In this paper we present the clinical findings of two
siblings from a Mexican family with only skeletal mani-
festations of MFS and screening analysis of the FBN1
gene variants [24]. Our patients are compared with the
previously reported clinical features of the same variant,
in order to determine the most frequent characteristics
associated to FBN1 R2726W variant [18–20]. We also
describe which features led us to classify these cases as
a type-1 fibrillinopathy related to Marfan-like skeletal
manifestations.
Case presentation
Patient 1. The proband was an 18 year old boy (Figs. 1a,
b, c and 2a (individual II:2)) who at the time of the first
evaluation was 16. On examination we found severe pec-
tus excavatum, scoliosis and a Marfan facial appearance
(malar hypoplasia, enophthalmos, retrognathia), as well
as elongated face, high arched palate and crowded teeth.
The proportion of segments was normal and he was of
normal height (25th–50th centile), had no cardiac symp-
toms He has remained asymptomatic with no chest pain,
syncope, or heart murmurs. No abnormalities were de-
tected on electrocardiograma or echocardiogram. Ocular
examination was normal, specifically lens placement was
normal and there was no evidence of myopia. Computed
Tomography (CT) imaging found there was no evidence
of dural ectasia or protusio acetabulae. Annual evalua-
tions since that time have failed to detect any cardiovas-
cular, ocular or systemic involvement. The proband did
not fulfill criteria for MFS or related disorders, since he
presented one major and two minor criteria of the skel-
etal system according to Ghent criteria, with a total of 3
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points for the score in the revised Ghent Criteria10–11.
We then evaluated the rest of the family members.
Patient 2. The proband’s sister (Figs. 1c and 2a (Individ-
ual II:3)), a 16 year old girl was diagnosed with moderate
pectus excavatum at 14 years of age. She also had some
Marfanoid facial features (enophthalmos, retrognathia
and malar hypoplasia). Height was normal (50th–75th
centile). She currently has no cardiovascular or ocular
abnormalities. According to Ghent criteria the patient
had two minor skeletal criteria and 2 points for the
revised score.
Clinical examination of the proband’s mother (Fig. 2a,
individual I:2) and brother (Fig. 2a, individual II:1) did not
show any skeletal or marfanoid features. Unfortunately
Fig. 1 Clinical features of the proband and his sister. a, b Clinical phenotype of the proband (II:2) including severe pectus excavatum, scoliosis
and some Marfan facial features. c Clinical phenotypes of the proband and his sister (II:3) including facial features
Fig. 2 Family pedigree and molecular characterization of the FBN1 variant. a Family pedigree. Black square and circle indicates the individuals
affected (II:2, II:3). b PCR-RFLP analysis of the R2726W FBN1 variant. The 214-bp amplification product was submitted to MspI cleavage. Lines 2 and
3, heterozygous variant (patients II:2 and II:3); lines 3 and 4, wild-type genotype (I:2 and II:1). MspI cleaves a 214-bp fragment into 27- and 187-bp
fragments in the presence of the C wild-type allele, whereas the T mutant allele is not cleaved. c The R2726W variant in exon 64 of
FBN1. Electropherogram showing the corresponding normal sequence in unaffected family members: a) Mother (I:1), b) brother (II:1), c and d) the C to T
heterozygous variant in II:2 and II:3, indicated by the arrow, resulting in the substitution of arginine by tryptophan (R2726W)
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the father (Fig. 2a, individual I:1) was not available for
clinical evaluation or sample collection.
Mutational screening
Genomic DNA was isolated from peripheral blood lym-
phocytes using the QIA amp DNA blood mini kit
(Qiagen, Inc) according to the manufacturer´s instructions.
All 65 exons of FBN1 were PCR amplified using specific
primers as described previously [8], and sequenced directly
using a DNA Sequencing Kit with Big Dye Terminator on
an automated ABI PRISM 3100 DNA sequencer (Applied
Biosystems, Foster City, CA, USA). To detect the R2726W
FBN1 variant by PCR-RFLP, a 214-bp fragment was
amplified by PCR using the following primers: 5'-GA
GTGTAAGATCAATGGCTACCCCAAC-3' (forward) and
5'-CTAGAGCTCAGGGAATGTCTGGAGTTTC-3' (re-
verse). Reaction parameters included 35 cycles of melting
at 94 °C for 30 s, annealing at 60 °C for 20 s, and extension
at 72 °C for 25 s, followed by a 5 min final extension at
72 °C. The forward primer contained an artificial cytosine
at the 3' end, which generates an MspI endonuclease rec-
ognition site. The R2726W (C to T transition at nucleo-
tide 8,176) substitution eliminates the MspI endonuclease
recognition site (Fig. 2). The 214-bp amplification product
was submitted to MspI cleavage, and the resultant frag-
ments were electrophoresed in a 2 % agarose gel contain-
ing ethidium bromide.
Molecular analyses
Mutational screening analysis in the proband revealed
the heterozygous c.C8176T transition in exon 64 of the
FBN1 gene, corresponding to R2726W variant in protein
FBN1, which leads to a single amino acid substitution of
tryptophan for arginine. His sister (Fig. 2a, individual II:3),
is heterozygous for the same variant. The mother and one
brother (Fig. 2a, individuals I:2 and II:1, respectively) did
not carry the R2726W variant [Fig. 2c]. PCR-RFLP ana-
lysis was used to confirm the R2726W FBN1 variant
found by direct sequencing in the proband II:2 (Fig. 2b).
Unfortunately, it was not possible to test the father, but
probably the variant is paternally inherited.
Discussion
Several pathogenic FBN1 variants have been identified in
MFS, affecting mostly the skeletal, ocular and cardiovascu-
lar systems [25–32]. However, there are families affected
with only one of these systems, carrying FBN1 inherited
variants [27–30] (i.e. ascending aortic aneurysm and dis-
section [27, 28], isolated ectopia lentis [28] and isolated
skeletal features [18–20]). The siblings presented here had
isolated skeletal features and were found to be hetero-
zygous for the R2726W FBN1 variant (rs61746008) in
exon 64, which has been previously reported in similarly
affected individuals. It encodes a region in the single
carboxy terminal domain of fibrillin that contains a recog-
nition motif for proteolytic tetrabasic cleavage, which
undergoes extracellular processing by an enzyme of the
PACE (Paired basic Amino acid Cleaving Enzyme) conver-
tase family. Furin/PACE specifically acts at the carboxy
terminal cleavage site of profibrillin-1 to convert it into
fibrillin [33, 34]. R2726W variant affects the processing
of profibrillin into fibrillin, and fibroblasts harbouring
this variant reduce fibrillin deposition in vivo, which re-
sults in a lack of its incorporation into microfibrils [18].
Up to now, families with 16 individuals affected by this
variant have been reported, showing variability in clin-
ical manifestations: some individuals manifested tall
stature, others skeletal abnormalities and others had no
clinical signs [18–20, 30–32].
The R2726W FBN1 variant was first described in 1995,
in a 13 year old patient with tall stature, pectus carinatum,
scoliosis, arachnodactyly and pes planus, leading to major
involvement of the skeletal system. Five additional mem-
bers of the family with the variant presented only with tall
stature, including one with metacarpal index above the
mean [18]. Additionally, in 2004, the R2726W FBN1
variant was reported in two individuals with average
height from one family [19]. The son (proband) inherited
the maternal variant and had a Marfan-like phenotype,
with skeletal, ocular and cardiac systems affected. Skeletal
manifestations were characterized by marfanoid habitus
and facial characteristics (dolichocephaly, malar hypo-
plasia, retrognathia, down-slanting palpebral fissures
and highly arched palate), pectus carinatum and medial
displacement of the medial malleolus causing pes planus.
Cardiac and ocular features were also present in the form
of prolapse of the leaflet of the tricuspid valve, mild
myopia and alternating exotropia. He also presented with
unrelated conditions including aggressive and hyperactive
behavior, a slight increase in the size of the cerebral ventri-
cles and the vermian cistern, developmental delay, child-
hood febrile and non-febrile seizures. The features in the
proband were suggestive of Lujan–Fryns syndrome. The
mother had a history of treated childhood seizures. It was
proposed that variant was associated with incomplete
penetrance.
In 2008, a female with mitral valve prolapse, myopia
and skin striae was reported [32]. In 2009, a family of
four affected individuals was described with two individ-
uals affected who were heterozygous for the R2726W
variant, which was also restricted to skeletal features of
MFS. The third affected family member was heterozygous
for a C1928S variant and the last one was compound het-
erozygous. Both satisfied the Ghent criteria, probably due
to the C1928S variant. The sibling who was heterozygous
for the R2726W FBN1 variant presented the following
clinical manifestations: mild scoliosis, articular hypermo-
bility, pes planus, highly arched palate, and mild pectus
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excavatum. The proband’s father, who also was heterozy-
gous, had mild pectus excavatum, wrist and thumb signs
[20]. In 2013, three members of a family were reported
where the proband had skeletal features of MFS in con-
junction with several birth defects, epilepsy, language and
behavior alterations attributable to the 17q21.31 microde-
letion. The father and sister who were also heterozygous
for the variant showed some skeletal features of MFS [31].
Finally, in 2014, another individual with MFS criteria was
reported, with a compound heterozygous genotype [30].
On Tables 1 and 2, we compared the skeletal charac-
teristics of all the heterozygous individuals previously
reported (13 cases), according to Ghent Criteria and the
Revised Ghent Criteria respectively. The most frequent
features are tall stature (4/13), pectus alterations (4/13),
facial appearance (3/10), kypho-scoliosis (3/13) and pes
planus (2/10). Only 3 had ocular features (myopia) and 2
cardiovascular features (tricuspid and mitral valve pro-
lapse). In this report, both siblings carrying the heterozy-
gous R2726W FBN1 variant are of average height. The
18 year old brother had a more severe phenotype com-
pared to the 16-year-old sister. They present clinical fea-
tures similar to the heterozygous son and father reported
by Dikj in 2004. The son was 17 years and presented with
kyphosis, both he and his father had pectus deformities
[22]. Including the siblings presented here to previously
reported cases, the most frequent clinical features were
pectus deformity (6/15), facial features (5/15), tall stature
(4/15) and kypho-scoliosis (4/15). Therefore, this variant
is clearly involved with skeletal manifestations of MFS. Al-
though it was not possible to test the father, it is likely that
the variant was paternally inherited.
Tables 1 and 2 clearly show that affected individuals
with this variant have clinical variability ranging from no
features (4/13) to isolated Marfan-like skeletal features
(9/13) and incomplete penetrance. This is consistent with
Bouni’s observations about R2726W variant, which is not
necessarily related to tall stature or Marfanoid habitus.
The variable expressivity is similar to that observed in
MFS, since 12–21 % of individuals with FBN1 variants
had incomplete MFS clinical criteria [9, 10].
The phenotypic diversity is also consistent with the
Universal Mutation Database [7], where to date over 1850
different FBN1 pathogenic variants related to MFS and its
associated disorders have been registered and the re-
corded R2716W variant was reported in conjunction with
no clinical features, skeletal manifestations or other fea-
tures. Looking for pathogenicity of some genetic variants
previously associated with Marfan syndrome, population
studies by next-generation sequencing found a prevalence
of 0.002 for R2627W variant in European Americans
and African Americans individuals [35]. The frequency
is similar in the ExAc database [36], with an allelic fre-
quency record of 0.00233 in Latin population and an
overall frequency of 0.00073 including different popula-
tions (in 60706 unrelated individuals), and 1 heterozygous
individual from America in 1000 genomes database from
26 different populations [37]. The low frequency of the
variant does not exclude it from causing disease, and
instead makes it a more credible cause.
Against the R2726W FBN1 variant potential patho-
genicity, are the heterozygous individuals without man-
ifestations in described families, the presence of the
variant in compound heterozygous state and one homozy-
gous individual reported in ExAC database. However,
there is no clinical description for the homozygous indi-
vidual in ExAC database, since only individuals affected by
severe pediatric disease have been removed. Variable ex-
pressivity and penetrance could rely on other factors. In
vitro experiments have demonstrated that the R2726W
FBN1 variant affects the cleavage mediated by Furin/
PACE and that profibrillin is unable to convert into fibril-
lin [33]. Of note, an in vitro study of R2726W/wild-type
FBN1 cells from a patient, had only half the amount of
normal fibrillin incorporated into the extracellular matrix,
resembling the effect of a non-expressed or “null” FBN1
allele [18]. However, the features ranging from no pheno-
type to isolated skeletal manifestation could be explained
by genetic modifiers of the wild-type FBN1 allele imply-
ing a role for haploinsufficiency in MFS, since the tetra-
basic consensus sequence is not absolutely required for
C-terminal processing of fibrillin-1. C-terminal processing
is not needed for fibrillin-1 function or utilization; modi-
fiers are subject to tissue-specific modifications [33, 35].
However, since FBN1 polymorphisms had been asso-
ciated with tall stature, and isolated scoliosis in non-
Marfan patients, clinical variability may be implied by
allelic variants in FBN1 expression or by certain FBN1
polymorphisms [38]. Alternatively, modifier genes, such
as TGF-β and FBN2, or even polymorphisms located in
the FBN1 gene may influence the penetrance or severity
of MFS [39]. Therefore, involved mechanisms affecting
the R2627W FBN1 variant expression could be similar,
and its penetrance may rely on the presence of other
variants in FBN1 or other genes involved in the same
pathway as suggested by Van Dijk et al. [20].
Skeletal manifestations have also been associated to
other variants. R1170H FBN1 variant has been reported in
a family with dolichostenomelia and arachnodactily [40]
and G1796E in a family with kyphoscoliosis and radio-
logical abnormalities of the spine, an unusual autosomal
dominant condition with variable and progressive severity,
without ocular or cardiac manifestations of MFS [41].
Although the number of reported cases of R2726W
variant is rare, we think the frequency of such phenotypes
may be underestimated. Reported cases to date point to
skeletal manifestations like kypho-scoliosis and pectus
deformities, as the most frequent features associated with
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Table 1 Clinical skeletal features of individuals affected with R2726W FBN1 mutation according to Ghent criteria
Individuals/Case number
Case number 1a 2a 3a 4a 5a 6a 7b 8b 9c 10d 11d 12d 13e 14e 15e 16f 17g 18g
Sex f m f m f m m f F m m m m f m m m f
Age 67 37 46 22 17 13 18 41 20 54 17 20 ND ND 21 19 18 16








Heigh (cm/TS) 169/- 193/+ 173/- 191/+ 175.2/+ 183/+ 178/- 164 ND/- ND/- ND/- ND/- ND/- ND/- 168/- ND/- 175/- 166/-
Skeletal features
Major -
Pectus carinatum - - - - + + - - - - - - - - - - -
Pectus excavatum
requiring surgery
- - - - - - - - - - + - - - - - -
Arm span to height
ratio >1.05
- - - - - - - - - - + - - - - - -
Wrist and thumb
signs
- - - - - - - - + - + - - - - - -
Scoliosis or
spondylolisthesis
- - - - - - - - - - + - + + - + -
Reduced extension
at the elbows
- - - - - - - - - - - - - - - - -
Pes planus - - - - - + - - - + + - - - - - -
Protrusio acetabulae
of any degree (RX)




- - - - - - - - + + - - - - - + +
Joint hypermobility - - - - - + - - - + + - - - - - -
High arched palate
with crowding of teeth














Table 1 Clinical skeletal features of individuals affected with R2726W FBN1 mutation according to Ghent criteria (Continued)
Facial appearance - - - - - - + - - - - + - - - + +
Cardiovascular features - - - - - - TVP - MVP - - AoDil,
AoDis
- - AI, BAV,
MVP
- -
Ocular features - - - - - - My, Ex - My - - My - My My - -
Additional features - - - MI - - AR, BA, ID,
Ep C, BD
Ep C St - HA HA, St Do, Ar Do, St Do, Ar,
Ep,




Individuals reported by: aMilewicz et al. 1995 [18]; bBuoni et al. 2004 [19]; cAttanasio et al. 2008 [32]; dVan Dijk 2009 [20]; eCallier et al. 2013 [31]; fPepe et al. 2014 [30]; gThis report
A plus sign (+) denotes feature present, a minus sign (−) denotes feature absent
Other abbreviations:
F female, m male
ND information not described
TS Tall stature
US/LS Upper segment/Lower segment
Microdel microdeletion
Facial features: Do Dolichocephaly, En Enophthalmos, DPF Downslanting palpebral fissures, MH Malar hypoplasia, R Retrognatia, HAP High arched palate, CT Crowded teeth, TVP Tricuspide valve prolapse, MPV Mitral
prolapse valve, AoDil Aorta dilatation, AoDis Aortic disection, BAV Bivalva aortic valve, AI Aortic insufficiency
My Myopia, Ex Exotropia
MI Metacarpal index above the mean
BA Behavior alterations
ID Intellectual disability
















Table 2 Clinical features of individuals affected with R2726W FBN1 variant, according to the Revised Marfan criteria
Individuals/Case number
Case number Score 1a 2a 3a 4a 5a 6a 7b 8b 9c 10d 11d 12d 13e 14e 15e 16f 17g 18g
Sex f m f m f m m f F m m m m f m m m f
Age 67 37 46 22 17 13 18 41 20 54 17 20 ND ND 21 19 18 16













1 − − − − − − − − − − − + − − − − − −
Wrist and thumb
sign
3 − − − − − − − − − + + + − − − − − −
Wrist or thumb
sign
1 − − − − − − − − − − − − − − + − − −
Pectus carinatum
deformity
2 + − − − − − + − − − − − − − − − − −
Pectus excavatum
or chest assymetry
1 − − − − − − − − − + + + − − − − + +
Hindfoot
deformity
2 − − − − − − + − − − − + − − − − − −
Pes planus 1 + − − − − − − − − − + + − − − − − −
Protrusio
acetabuli









1 + − − − − − − − − − + − − + CT − + −
Reduced elbow
extension
1 − − − − − − − − − − − − − HAP − − − −



















- - - - - - TVP − MVP − − AoDil,
AoDis
− − AI, BAV,
MVP
− −
Ocular features − − − − − − My, Ex − My − − My − My My − −
Additional features − − − MI − − AR, BA,
ID, Ep
C, BD
Ep C St − HA HA, St Do, Ar Do, St Do, HA,
Ar, Ep,




Individuals reported by: aMilewicz et al. 1995 [18]; bBuoni et al. 2004 [19]; cAttanasio et al. 2008 [32]; dVan Dijk 2009 [20]; fPepe 2014 [30]; gThis report
A plus sign (+) denotes feature present, a minus sign (−) denotes feature absent
Other abbreviations:
F female, m male
ND information not described
TS Tall stature
US/LS Upper segment/Lower segment
Microdel microdeletion
Facial features: Do Dolichocephaly, En Enophthalmos, DPF Downslanting palpebral fissures, MH Malar hypoplasia, R Retrognatia, HAP High arched palate, CT Crowded teeth, TVP Tricuspide valve prolapse, MPV Mitral
prolapse valve, AoDil Aorta dilatation, AoDis Aortic disection, BAV Bivalva aortic valve, AI Aortic insufficiency
My Myopia, Ex Exotropia





















the variant R2726W, therefore, families with this features
should be screened for this variants regardless of the pres-
ence or absence of tall stature or Marfanoid habitus.
It is important to note that there was no follow up
data available on any of the reported cases and, thus is
possible that some individuals subsequently developed
other MFS manifestations. Additional data needs to be
gathered on other individuals carryng the data including
follow up evaluations in order to better characterize the
phenotype associated with this genotype. Since MFS
phenotype appears in the first two decades of life, and
since some of them have cardiovascular and ocular man-
ifestations, it would be important to monitor carriers
and to determine if they have cardiac, ocular or other
system involvement, or if they complete clinical criteria
for MFS. If they continue without changes, we could con-
sider a R2627W FBN1 variant related to Marfan-like
skeletal manifestations. Also, in agreement with Faivre, a
patient with isolated skeletal phenotype and R2726W
variant could be classified as having type I fibrillinopathy.
Nonetheless, given the significant phenotypic variability
between and within families, wether attributable to com-
pound heterozygosity or the presence of other possible
modifiers in FBN1 and related genes, cautious ongoing
surveillance is always prudent.
Conclusion
We confirmed the R2726W FBN1 variant in siblings with
isolated Marfan-like skeletal features. All clinical features
for the reported cases support the expansion of the type-1
fibrillin related disorders, and reinforce the importance of
skeletal findings in clinical practice in order to identify in-
dividuals with a possible fibrillinopathy. Findings in these
siblings still show the clinical variability observed for this
variant, and denote the FBN1 sequence screening utility.
Certainly, these cases represent a diagnostic challenge,
and for individuals with this kind of skeletal abnormalities,
the molecular mutation detection is necessary to establish
the final diagnosis. The R2726W variant identification can
be a valuable diagnostic aid in uncertain cases. Variant
identification for the siblings we reported was helpful for
genetic counseling, and appropriate follow up.
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